REMOVAB.COM
Home - Removab®Information for healthcare professionals on Removab® (catumaxomab) treatment of malignant ascites.
http://www.removab.com/
Information for healthcare professionals on Removab® (catumaxomab) treatment of malignant ascites.
http://www.removab.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
0.8 seconds
Fresenius BioTech GmbH
Am ●●●g 6
Grae●●●●fing
DE
View this contact
v3-agentur fuer medizinisches marketing GmbH
Daniela Christmann
Strasse d●●●●●●●●●i 106-108
Be●●in
DE
View this contact
v3-agentur fuer medizinisches marketing GmbH
Daniela Christmann
Strasse d●●●●●●●●●i 106-108
Be●●in
DE
View this contact
v3-agentur fuer medizinisches marketing GmbH
Daniela Christmann
Strasse d●●●●●●●●●i 106-108
Be●●in
DE
View this contact
BUY YOUR DOMAIN
HETZNER ONLINE AG
WHOIS : whois.your-server.de
REFERRED : http://www.hetzner.de
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
6
SITE IP
78.46.2.123
LOAD TIME
0.816 sec
SCORE
6.2
Home - Removab® | removab.com Reviews
https://removab.com
Information for healthcare professionals on Removab® (catumaxomab) treatment of malignant ascites.
Fresenius Biotech obtains reimbursement approval for Removab
http://www.neoviibiotech.info/press/press-report/items/fresenius-biotech-obtains-reimbursement-approval-for-removab-antibody-in-belgium.html
Neovii Biotech: Press report. Fresenius Biotech obtains reimbursement approval for Removab. The Belgian Ministry of Social Affairs and Public Health has added the trifunctional antibody Removab. Was also approved for reimbursement in Italy in June. The positive reimbursement decision in Belgium follows a comprehensive appraisal process that thoroughly assessed both the clinical value as well as the cost-effectiveness of Removab. Is under further development for new indications. Catumaxomab (Removab.
ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab
http://www.neoviibiotech.info/press/press-report/items/asco-2011-fresenius-biotech-presents-new-data-for-the-trifunctional-antibody-removabsupsup-benefit-in-overall-survival-of-cancer.html
Benefit in overall survival of cancer patients demonstrated. Neovii Biotech: Press report. ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab. Benefit in overall survival of cancer patients demonstrated. At the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (June 3-7, 2011), Fresenius Biotech presented new data on the trifunctional antibody Removab. Significant overall survival benefit in patients with higher relative lymphocyte count.
ESMO 2012: New phase IIIb study confirms the shorter infusion time, efficacy and safety of catumaxomab in malignant ascites
http://www.neoviibiotech.info/press/press-report/items/esmo-2012-new-phase-iiib-study-confirms-the-shorter-infusion-time-efficacy-and-safety-of-catumaxomab-in-malignant-ascites.html
Neovii Biotech: Press report. ESMO 2012: New phase IIIb study confirms the shorter infusion time, efficacy and safety of catumaxomab in malignant ascites. Robust data confirm the clinical relevance. Of 35 days (95% CI, 26-59). The median puncture-free time was 97 days, i.e. over 3 months (95% CI, 67-155). The median overall survival was 103 days (95% CI, 82 to 133). [1]. Safety profile of the 3 h infusion i.p. confirmed. Improved quality of life after treatment with catumaxomab. Binds to Fc receptors on ...
Fresenius Biotech obtains reimbursement approval for Removab
http://www.neoviibiotech.info/press/press-report/items/fresenius-biotech-obtains-reimbursement-approval-for-removab-antibody-in-italy.html
Neovii Biotech: Press report. Fresenius Biotech obtains reimbursement approval for Removab. The Italian Medicines Agency, AIFA, has added Fresenius Biotech’s antibody Removab. To its list of reimbursable medications. As of June 25, 2011, use of Removab. For the treatment of malignant ascites in patients with EpCAM-positive carcinomas will be fully reimbursed. Removab. Said Dr. Christian Schetter, CEO of Fresenius Biotech. It enables patients in Italy to benefit from treatment with Removab. Is to generate...
Fresenius Biotech presents new data on trifunctional antibody Removab
http://www.neoviibiotech.info/press/press-report/items/fresenius-biotech-presents-new-data-on-trifunctional-antibody-removab-at-46th-asco-annual-meeting-in-chicago.html
At 46th ASCO Annual Meeting in Chicago. Neovii Biotech: Press report. Fresenius Biotech presents new data on trifunctional antibody Removab. At 46th ASCO Annual Meeting in Chicago. Fresenius Biotech presents new data on trifunctional antibody Removab. At 46th ASCO Annual Meeting in Chicago. Shows doubling of survival in patients with early immune response. Therapy feasible in early approaches to ovarian cancer treatment. Eight days after conclusion of a four-dose intraperitoneal therapy. Results show...
Removab
http://www.neoviibiotech.info/press/press-report/items/removab-receives-approval-for-a-shorter-infusion-time-in-treating-malignant-ascites-one-year-survival-rate-in-removab.html
Receives approval for a shorter infusion time in treating malignant ascites one-year survival rate in Removab. Treated patients is more than four times higher. Neovii Biotech: Press report. Receives approval for a shorter infusion time in treating malignant ascites one-year survival rate in Removab. Treated patients is more than four times higher. The European Commission has broadened the existing approval of Fresenius Biotech’s antibody Removab. Was administered intraperitoneally as three or six-hour in...
TOTAL LINKS TO THIS WEBSITE
6
Remova.Me | Suporte a vítimas
Removemos fotos e vídeos de vítimas na internet. Ajudamos vítimas na reconstrução do seu caminho. Conheça a Remova.me. Sobre a Remova.me. Somos a empresa pioneira no Brasil de suporte às vítimas de crimes virtuais como cyberbullying, revenge porn e invasão de privacidade. Aliando alta tecnologia ao direito eletrônico, somos inovadores na criação de recurso simplificado para solução do seu problema da maneira mais rápida e eficiente possível. A Remova.me é pioneira mundialmente em desenvolver um proto...
Remova.net
The domain remova.net may be for sale. Click here to make an offer or call 877-588-1085 to speak with one of our domain experts. This domain may be for sale. Buy this Domain.
remova1ists.net - Crazy Domains
Search and register domain names. World's cheapest domain names. 700 New generic domains. Move your domains to us FREE. Express cheap domain renewal. Get the domain name you want. Everything you need for your domains. Control your CNAME, MX and A records. Find who owns a particular domain. COM only $9.00 Get yours! Join The Domain Club. Fast, reliable space for your website. Defend your site against hackers. Secure your site and data. Get your own me@mydomain.com. Automatic Spam and Virus protection.
remova1s.com - Crazy Domains
Search and register domain names. World's cheapest domain names. 700 New generic domains. Move your domains to us FREE. Express cheap domain renewal. Get the domain name you want. Everything you need for your domains. Control your CNAME, MX and A records. Find who owns a particular domain. COM only $9.00 Get yours! Join The Domain Club. Fast, reliable space for your website. Defend your site against hackers. Secure your site and data. Get your own me@mydomain.com. Automatic Spam and Virus protection.
remova1s.net - Crazy Domains
Search and register domain names. World's cheapest domain names. 700 New generic domains. Move your domains to us FREE. Express cheap domain renewal. Get the domain name you want. Everything you need for your domains. Control your CNAME, MX and A records. Find who owns a particular domain. COM only $9.00 Get yours! Join The Domain Club. Fast, reliable space for your website. Defend your site against hackers. Secure your site and data. Get your own me@mydomain.com. Automatic Spam and Virus protection.
Home - Removab®
ASCO 2013: Dr. Gregor Dresemann. ASCO 2013: Prof. Ignace Vergote. CASIMAS-study: Prof. Florian Lordick. ASCO 2012: PD Dr. Oskay. Prof Dr. Markus M. Heiss. If you would like to learn more about malignant ascites and trifunctional antibody Removab , please follow the links below or contact your physician. The following information on Removab (catumaxomab) is intended for healthcare professionals only. You must login to access this page. Patient brochure Removab (1.0 MB). 2015 Neovii Biotech GmbH.
Home - Removab®
ASCO 2013: Dr. Gregor Dresemann. ASCO 2013: Prof. Ignace Vergote. CASIMAS-study: Prof. Florian Lordick. ASCO 2012: PD Dr. Oskay. Prof Dr. Markus M. Heiss. If you would like to learn more about malignant ascites and trifunctional antibody Removab , please follow the links below or contact your physician. The following information on Removab (catumaxomab) is intended for healthcare professionals only. You must login to access this page. Patient brochure Removab (1.0 MB). 2015 Neovii Biotech GmbH.
This domain has no active presence
Sorry for any inconvenience. This domain has no active presence.
removable-bollards.blogspot.com
Removable Bollards and Barriers
Removable Bollards and Barriers. What's New for Our Removable Bollards Many things have changed in our Country since 9-11 and the need for a simple removable Security and vehicular control is just one example. Friday, September 30, 2005. Removable Bollards for Homeland Security and Vehicular Control. Many things have changed in our Country since 9-11 and the need for a simple removable Security and vehicular control is just one example. Or http:/ atecdiversified.com/bollards/. Posted by David at 5:13 AM.
REMOVABLE DENTURES - Contact
IULIU KOVACS, DD. 5 FAIRVIEW MALL DRIVE. Suite 130 (on Main Floor). North York, M2J 2Z1, ON. For a consultation please call:. Or send us an e-mail:.
removable-holds.com at Directnic
